Shots:

• The transition to the second phase of development follows the completion of the first phase of securing 300 different types of Abs targeting the antigen last month. The library of Ab was developed utilizing the blood of recovered patients in Korea
• Celltrion will initiate the screening of Ab to find the most effective one in neutralizing SARS-CoV-2 in collaboration with the Korea Centers for Disease Control and Prevention
• Celltrion expects to complete the candidate screening for mAb by mid-April and plans to initiate the clinical trials in July’2020

Click here ­to­ read full press release/ article | Ref: Celltrion  | Image: Celltrion